Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05624099 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 19, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Oct 1, 2023 to Aug 1, 2023v4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 6 more changesShow less
    • Enrollment target: 226 to 75
    • Start date: Dec 1, 2022 to Oct 1, 2023
    • Study sites: 0 to 1
    • Interventions: Camrelizumab (Drug), Paclitaxel (Drug), Platinum (Drug), Radiotherapy (Radiation) to Paclitaxel drugs (Drug), Platinum drug (Drug), Radiation (Radiation), camrelizumab (Drug)
    • Eligibility criteria shortened, about 14 words
    • Study arms: 2 to 1
  3. Eligibility criteria revised
    • Study title shortened, about 14 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Trial Details
NCT Number NCT05624099
Lead Sponsor Fujian Cancer Hospital
Conditions
(from sponsor)		 Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
Related terms Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov